A Phase I Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 With or Without PD-1 Blockade for HPV-Associated Cancers

Trial Profile

A Phase I Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 With or Without PD-1 Blockade for HPV-Associated Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Anti-HPV-16 E7 T cells (Primary) ; Cyclophosphamide; Fludarabine; Pembrolizumab; Pembrolizumab
  • Indications Anal cancer; Cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Feb 2017 Planned number of patients changed from 40 to 180.
    • 12 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top